Tetrahydrocannabinol (Delta 9-THC) Treatment in  Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

<table>Psychometric assessment of the patients before (white bar) and during/after (black bar) delta 9-THC therapy. Particularly Pain Disability Index (PDI), Quality of Life (QLIP), and Hospital Anxiety Depression Scale (HADS) improved significantly in response to delta 9-THC treatment.</table>

Anesthesiology Research and Practice

fig2

Figure 2

Figure 2: Tetrahydrocannabinol (Delta 9-THC) Treatment in  Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey 

Figure 2 | Tetrahydrocannabinol (Delta 9-THC) Treatment in  Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey 